Use of artemisinin and its derivatives to treat HPV-infected/transformed cells and cervical cancer: a review.

Cervical cancer and HPV-related diseases remain a burden in the developing world. While much progress has been gained in the detection of HPV and preneoplastic cervical lesions, the rate-limiting step in the prevention of cervical cancer is management of these women. A natural compound, artemisinin, and its derivatives appear to hold promise as a simple means of treatment. Laboratory studies have shown that this compound, and its derivatives, have activity against HPV-infected and -transformed cells and cervical cancer cells. In situations of compassionate use, studies have also demonstrated efficacy in clinical situations. Well-designed clinical trials relating to its use should be undertaken.

[1]  M. Tanner,et al.  Artemisinins for schistosomiasis and beyond. , 2007, Current opinion in investigational drugs.

[2]  Liu Yang,et al.  Study on the radiosensitizing effect of artemisinin on human cervical cancer and corresponding mechanisms. , 2009 .

[3]  R. Breitling,et al.  Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. , 2010, Biochemical pharmacology.

[4]  T. Efferth,et al.  Cytotoxic activity of secondary metabolites derived from Artemisia annua L. towards cancer cells in comparison to its designated active constituent artemisinin. , 2011, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[5]  A. Östör,et al.  Natural history of cervical intraepithelial neoplasia: a critical review. , 1993, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[6]  S. Wacholder,et al.  CIN2 Is a Much Less Reproducible and Less Valid Diagnosis than CIN3: Results from a Histological Review of Population-Based Cervical Samples , 2007, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[7]  Hui-jun Zhou,et al.  Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. , 2003, Pharmacological research.

[8]  S. Fu,et al.  Selective Radiosensitization of Human Cervical Cancer Cells and Normal Cells by Artemisinin Through the Abrogation of Radiation-Induced G2 Block , 2012, International Journal of Gynecologic Cancer.

[9]  Narendra Singh,et al.  Case report of a laryngeal squamous cell carcinoma treated with artesunate , 2002 .

[10]  G. Firestone,et al.  Anticancer activities of artemisinin and its bioactive derivatives , 2009, Expert Reviews in Molecular Medicine.

[11]  A. R. Chang,et al.  Carcinoma in situ of the cervix and its malignant potential. A lesson from New Zealand , 1990, Cytopathology : official journal of the British Society for Clinical Cytology.

[12]  Richard Schlegel,et al.  Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. , 2005, Cancer research.

[13]  T. Efferth,et al.  First study of oral Artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers. , 2011, Anticancer research.

[14]  K. Lakshmaiah,et al.  HPV screening for cervical cancer in rural India. , 2009, The New England journal of medicine.

[15]  W. F. Zheng,et al.  Biologically Active Substances from the Genus Artemisia , 1998, Planta medica.

[16]  K. Shah,et al.  Looking ahead: A case for human papillomavirus testing of self‐sampled vaginal specimens as a cervical cancer screening strategy , 2011, International journal of cancer.

[17]  M. Stanley.  Pathology and epidemiology of HPV infection in females. , 2010, Gynecologic oncology.

[18]  Y. Qiao,et al.  Human papillomavirus testing for cervical cancer screening: results from a 6-year prospective study in rural China. , 2009, American journal of epidemiology.

[19]  Narendra Singh,et al.  Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds , 2005, Expert opinion on therapeutic targets.

[20]  Y. Qiao,et al.  Prevalence of type‐specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self‐collected specimens: Implications for vaginal self‐collection , 2009, International journal of cancer.

[21]  T. Efferth,et al.  The anti-malarial artesunate is also active against cancer. , 2001, International journal of oncology.

[22]  K. Tew,et al.  Molecular modes of action of artesunate in tumor cell lines. , 2003, Molecular pharmacology.

[23]  T. Wright,et al.  The costs of reducing loss to follow-up in South African cervical cancer screening , 2005, Cost effectiveness and resource allocation : C/E.

[24]  T. Rohan,et al.  Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. , 1999, The Journal of infectious diseases.

[25]  J. Ordi,et al.  Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. , 2011, Gynecologic oncology.

[26]  P. Carmeliet,et al.  Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties , 2010, Journal of cellular and molecular medicine.

[27]  Hui Wang,et al.  Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action , 2008, Clinical Cancer Research.

[28]  P. Sasieni,et al.  Assessing participation of women in a cervical cancer screening program in Peru. , 2009, Revista panamericana de salud publica = Pan American journal of public health.

[29]  Bin Yang,et al.  Secondary Screening After Primary Self-Sampling for Human Papillomavirus From SHENCCAST II , 2012, Journal of lower genital tract disease.

[30]  M. Jung,et al.  Recent advances in artemisinin and its derivatives as antimalarial and antitumor agents. , 2004, Current medicinal chemistry.

[31]  Roy Zhang,et al.  Performance of p16/Ki-67 Immunostaining to Detect Cervical Cancer Precursors in a Colposcopy Referral Population , 2012, Clinical Cancer Research.

[32]  T. Efferth,et al.  Factors determining sensitivity or resistance of tumor cell lines towards artesunate. , 2010, Chemico-biological interactions.

[33]  Z. Y. Song,et al.  [Pharmacokinetics of dihydroqinghaosu in human volunteers and comparison with qinghaosu]. , 1993, Yao xue xue bao = Acta pharmaceutica Sinica.

[34]  T. Efferth,et al.  Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. , 2004, Biochemical pharmacology.

[35]  B. Hambly,et al.  Dihydroartiminisin inhibits the growth and metastasis of epithelial ovarian cancer. , 2011, Oncology reports.

[36]  Y. Qiao,et al.  Shanxi Province cervical cancer screening study II: Self‐sampling for high‐risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[37]  J. Davis,et al.  Factors that affect the quality of cytologic cervical cancer screening along the Mexico-United States border. , 2003, American journal of obstetrics and gynecology.

[38]  K. Bora,et al.  The Genus Artemisia: A Comprehensive Review , 2011, Pharmaceutical biology.

[39]  S. Wacholder,et al.  Human papillomavirus testing in the prevention of cervical cancer. , 2011, Journal of the National Cancer Institute.

[40]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[41]  T. Efferth.  Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. , 2006, Current drug targets.

[42]  D. Oda,et al.  Artemisinin: an alternative treatment for oral squamous cell carcinoma. , 2004, Anticancer research.

[43]  M. Wei,et al.  Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug , 2011, Journal of biomedicine & biotechnology.

[44]  F. Oesch,et al.  Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. , 2004, Free radical biology & medicine.

[45]  H. Skomedal,et al.  High-Risk Human Papillomavirus (hrHPV) E6/E7 mRNA Testing by PreTect HPV-Proofer for Detection of Cervical High-Grade Intraepithelial Neoplasia and Cancer among hrHPV DNA-Positive Women with Normal Cytology , 2012, Journal of Clinical Microbiology.

[46]  P. Lumbiganon,et al.  Loss to follow-up of patients with abnormal Pap smear: magnitude and reasons. , 1998, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[47]  T. Wright,et al.  Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. , 2011, American journal of clinical pathology.

[48]  T. Efferth.  Willmar Schwabe Award 2006: Antiplasmodial and Antitumor Activity of Artemisinin - From Bench to Bedside , 2007, Planta medica.

[49]  Ying Li,et al.  An over four millennium story behind qinghaosu (artemisinin)--a fantastic antimalarial drug from a traditional chinese herb. , 2003, Current medicinal chemistry.

[50]  W. Hong,et al.  The natural history of cervical intraepithelial neoplasia: an argument for intermediate endpoint biomarkers. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[51]  X. Yi,et al.  Improved sensitivity of vaginal self‐collection and high‐risk human papillomavirus testing , 2012, International journal of cancer.

[52]  T. Efferth,et al.  Artesunate derived from traditional Chinese medicine induces DNA damage and repair. , 2008, Cancer research.